Eloxx Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Watertownmassachusettswith A Research And Development Center In Rehovotisraelthe Company Focuses On Developing Rna Modulating Therapies For Rare And Ultra Rare Genetic Diseases Caused By Premature Stop Codon Mutationseloxx Aims To Restore Functional Protein Production In Patients Suffering From Severe Genetic Disorders The Company Specializes In Eukaryotic Ribosomal Selective Glycosidesersgs Which Are Small Molecule Drug Candidates Designed To Enable Ribosomal Read Through Of Premature Stop Codonseloxx S Lead Investigational Drugelx 02Is Currently In Phase Ii Trials For Cystic Fibrosis Caused By Nonsense Mutationsthe Company Is Also Advancing Preclinical Candidates Targeting Conditions Such As Autosomal Dominant Polycystic Kidney Disease And Usher Syndromeeloxx Employs Proprietary Platformsincluding Turbo Zm And Ribosome Modulating Agentsto Enhance Drug Delivery And Efficacy For Tissue Specific Targeting
